涩里番

Every year, billions of dollars are invested by funding agencies in basic and translational research, yet the path from academic discovery to private investment necessary for the creation of new companies is rarely straightforward. In this seminar, you'll get an inside look at how investors work, what makes a research idea stand out to venture capitalists, and how they evaluate translational value of scientific opportunities. By the end of the session, you鈥檒l have a clearer grasp of the framework needed to transition an idea or mechanism discovered in the lab to an investment phase.

This event is can be attended in-person at D2R Offices (1010 Sherbrooke St. West, Suite 1800, 18th floor) OR virtually on Zoom.

About the Speaker

In猫s Holzbaur

In猫s Holzbaur is Founder and Managing Partner of AmorChem. She was instrumental in creating the innovative investment model of this early-stage life science fund, as well as in developing its operations and investment process. In猫s is passionate about bringing early-stage life science investments to fruition and was actively involved in transactions with large pharmaceutical companies, such as Hoffman LaRoche and Vertex Pharmaceuticals. As part of her role at AmorChem, she was a founder of NuChem Sciences, serving as Chair of its Board of Directors from 2011-2019.

Her dedication to life science extends beyond AmorChem: she recently joined the Investment and Commercialization Committee of the DNA to RNA | D2R initiative at 涩里番 and serves as Vice-Chair of the Board of both the Quebec Biotechnology Innovation Centre and G茅nome Qu茅bec. Furthermore, she is an active participant in Montreal InVivo committees and is frequently asked to mentor and teach aspiring biotech professionals.

Her early-stage expertise is valued in other technological areas as well: in cleantech through her role as Chair of the Investment Committee of Cycle Momentum and in artificial intelligence through her past participation in Creative Destruction Lab. In addition, her efforts extend beyond Quebec: she had the pleasure of acting as Chair of the Nanomedicine Innovation Network and is a member of the College of Reviewers of the Canadian Institutes of Health Research and of ZonMW, a Dutch granting agency.

After joining the venture capital industry in the late 1990s as an intern for the GeneChem family of funds, she quickly rose to Partner and invested in Canada, the UK and the US. The solid reputation she built as an investor was recognized through her election to the Board of R茅seau-Capital from 2014-2020. In猫s holds a PhD in Chemistry from the University of Cambridge, a Certificate in Leadership from the Institute of Corporate Directors as well as a Certificate in Private Capital Governance from the Canadian Venture Capital Association.

Register

Be part of the discussion with AmorChem!

Confirmation emails will be provided to registered participants a few days before the event.